EUDAMED: Four Modules Due To Come Online By Mid-2021
The medtech sector is getting impatient with the European Commission’s frequent changes in the launch date for the new Eudamed medical device database, a foundation stone for the new regulations. The commission has just announced an ambitious new timetable.
The European Commission gave insights on a current update of their EUDAMED website:
“What is the state of play of the implementation of EUDAMED?
- The development and implementation of EUDAMED is a high priority for the Commission.
- We have pledged, in agreement with the MDCG, to gradually make the different modules available as soon as they are functional.
- We will make the module on actor registration available first, deploying it by March 2021 at the latest.
- We will make the module on UDI/device registration (second module) and the module on certificates and notified bodies (third module) available by May 2021. The remaining modules will become available afterwards as soon as they are functional.”
MEDTECHDIVE reports that The Commission last year delayed the introduction of its database of medical device information until May 2022 after coming to accept it would miss its original target. Since then, EU authorities have delayed the date of application for MDR until 2021, but that still leaves a 12-month window in which the new regulations will be in force in the absence of a database intended to be key to their functioning.
On Wednesday, MDCG cleared up how one aspect of MDR will work prior to the Eudamed launch. The guidance states sponsors will use “a new template for the Summary Reporting Form” to share details of certain adverse events and product deficiencies linked to their investigational devices.
It will be impossible to generate the EU-wide Single Identification Numbers referenced in MDR until Eudamed is fully functional, leading MDCG to propose assigning tracking numbers to clinical trials when they are registered in the existing medical device databank. Sponsors will then use the tracking numbers, known as CIV IDs, to identify clinical trials in safety reports.
The guidance details the information MDCG expects sponsors to include in reports and touches on what will happen when Eudamed belatedly goes live. Once the Commission has formally confirmed Eudamed to be fully functional, sponsors will have six months to start reporting via the database.
Even with that transition period, MDCG acknowledges that some reports filed using the Summary Reporting Form will remain active at the point that Eudamed becomes mandatory. Sponsors in that position will continue to use the old process to file follow-up events and final reports, but must use Eudamed for wholly new submissions.
It is unclear whether events submitted using a Summary Reporting Form in the possible 18-month window between the MDR date of application and Eudamed becoming mandatory will ever become part of the database. In theory, events filed before Eudamed becomes mandatory could be added to the database retrospectively. However, MDCG said it is unclear whether that will be possible.
Please find the complete article here.
Please get in touch with us: